First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
Authors:
- Bruce HughesBHBruce Hughes
- Mark CascioneMCMark Cascione
- Mark S. FreedmanMFMark S. Freedman
- Mark AgiusMAMark Agius
- Daniel KantorDKDaniel Kantor
- Mark GudesblattMGMark Gudesblatt
- Lawrence P. GoldstickLGLawrence P. Goldstick
- Neetu AgashivalaNANeetu Agashivala
- Lesley SchofieldLSLesley Schofield
- Kevin McCagueKMKevin McCague
- Ron HashmonayRHRon Hashmonay
- Luigi BarbatoLBLuigi Barbato
- 1 September 2014
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 3 (5) , 620-628
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisMultiple Sclerosis and Related Disorders, 2014
- Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trialBMC Neurology, 2014
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label studyJournal of Neurology, 2013
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 2010
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacologyPharmacology & Therapeutics, 2007
- Oral Fingolimod (FTY720) for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Rating neurologic impairment in multiple sclerosisNeurology, 1983